BioMotiv
Accelerating Breakthrough Discoveries into Medicines

BioMotiv Blog

Recognizing World Cancer Day

Many of the companies in BioMotiv’s portfolio are currently working on therapies for the treatment of various forms of cancer. In recognition of World Cancer Day (February 4), here’s a quick overview of the work our team is doing to bring potential new treatments to the patients who need them most.

ARO Full Color Logo 2018SEP05 F .jpg
 



Aro Biotherapeutics

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Aro was established through an initial start-up investment from Johnson & Johnson Innovation and BioMotiv. Click to learn more.

Optikira logo.JPG


OptiKira

OptiKira is advancing discoveries made by a team from The University of California, San Francisco and the University of Washington. Extensive research by our academic founders and others has defined the central role of the unfolded protein response (UPR) pathway in the progressive cell death which characterizes diseases such as pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), diabetes, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), cancer, and retinitis pigmentosa. Click to learn more.

SapVax - Logo 20170324.png


SapVax

SapVax is developing a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology. Based on intellectual property licensed from the University of Auckland, the Sapvax team is developing a pipeline of products for the treatment of different cancers. Click to learn more.

Erin Reese